Literature DB >> 12679918

Pre-operative radiochemotherapy of locally advanced rectal cancer.

Xiao-Nan Sun1, Qi-Chu Yang, Jian-Bin Hu.   

Abstract

AIM: To evaluate results of pre-operative radiochemotherapy followed by surgery for 15 patients with locally advanced un-resectable rectal cancer.
METHODS: 15 patients with advanced non-resectable rectal cancer were treated with pre-operative irriadiation of 40-46 Gy plus concomitant chemotherapy (5-FU+LV and 5'-DFuR) (RCS group). For comparison, 27 similar patients, treated by preoperative radiotherapy (40-50 Gy) plus surgery were served as control (RS group).
RESULTS: No radiochemotherapy or radiotherapy was interrupted and then was delayed because of toxicities in both groups. The radical resectability rate was 73.3 % in the RCS group and 37.0 % (P=0.024) in RS group. Sphincter preservation rates were 26.6 % and 3.7 % respectively (P=0.028). Sphincter preservation rates of lower rectal cancer were 27.3 % and 0.0 % respectively (P=0.014). Response rates of RCS and RS groups were 46.7 % and 18.5 % (P=0.053). The tumor downstage rates were 8 (53.3 %) and 9 (33.3 %) in these groups (P=0.206). The 3-year overall survival rates were 66.7 % and 55.6 % (P=0.485), and the disease free survival rates were 40.1 % and 33.2 % (P=0.663). The 3-year local recurrent rates were 26.7 % and 48.1 % (P=0.174). No obvious late effects were found in either groups.
CONCLUSION: High resectability is possible following pre-operative radiochemotherapy and can have more sphincters preserved. It is important to improve the quality of the patients' life even without increasing the survival or local control rates. Preoperative radiotherapy with concomitant full course chemotherapy (5-Fu+LV and 5'-DFuR) is effective and safe.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679918      PMCID: PMC4611436          DOI: 10.3748/wjg.v9.i4.717

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Preoperative radiotherapy in rectal carcinoma--aspects of acute adverse effects and radiation technique.

Authors:  G J Frykholm; U Isacsson; K Nygård; A Montelius; B Jung; L Påhlman; B Glimelius
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-07-15       Impact factor: 7.038

Review 2.  Aggressive multimodality treatment for locally advanced irresectable rectal cancer.

Authors:  R Farouk; H Nelson; L L Gunderson
Journal:  Br J Surg       Date:  1997-06       Impact factor: 6.939

Review 3.  Indications for and results of combined modality treatment of colorectal cancer.

Authors:  L L Gunderson
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

4.  Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.

Authors:  A Tsuji; S Morita; T Horimi; M Takasaki; I Takahashi; T Shirasaka
Journal:  Gan To Kagaku Ryoho       Date:  2000-05

5.  Patient preferences for oral versus intravenous palliative chemotherapy.

Authors:  G Liu; E Franssen; M I Fitch; E Warner
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

Review 6.  The medical treatment of colorectal cancer: actual status and new developments.

Authors:  E Van Cutsem; M Peeters; C Verslype; L Filez; K Haustermans; J Janssens
Journal:  Hepatogastroenterology       Date:  1999 Mar-Apr

7.  Use of Carcinoembryonic Antigen Gene Promoter in Colorectal Carcinoma-specific Suicidal Gene Therapy.

Authors:  Qiong Jiang; Kai Ge; De-Hua Xu; Lan-Ying Sun; Zhong-Cheng Zheng; Xin-Yuan Liu
Journal:  Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)       Date:  1998

8.  Preoperative irradiation and fluorouracil chemotherapy for locally advanced rectosigmoid carcinoma: phase I-II study.

Authors:  J C Landry; M J Koretz; W C Wood; S Bahri; R G Smith; M Costa; G W Daneker; M R York; P R Sarma; M Lynn
Journal:  Radiology       Date:  1993-08       Impact factor: 11.105

9.  Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation.

Authors:  E T Chen; M Mohiuddin; H Brodovsky; G Fishbein; G Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-08-30       Impact factor: 7.038

10.  Preoperative infusional chemoradiation therapy for stage T3 rectal cancer.

Authors:  T A Rich; J M Skibber; J A Ajani; D J Buchholz; K R Cleary; R A Dubrow; B Levin; P M Lynch; S H Meterissian; L D Roubein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-15       Impact factor: 7.038

View more
  5 in total

1.  Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer.

Authors:  Jian-Bin Hu; Xiao-Nan Sun; Qi-Chu Yang; Jing Xu; Qi Wang; Chao He
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

2.  Comparative evaluation of immune response after laparoscopical and open total mesorectal excisions with anal sphincter preservation in patients with rectal cancer.

Authors:  Jian-Kun Hu; Zong-Guang Zhou; Zhi-Xin Chen; Lan-Lan Wang; Yong-Yang Yu; Jin Liu; Bo Zhang; Li Li; Ye Shu; Jia-Ping Chen
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

3.  Differentially expressed proteins of gamma-ray irradiated mouse intestinal epithelial cells by two-dimensional electrophoresis and MALDI-TOF mass spectrometry.

Authors:  Bo Zhang; Yong-Ping Su; Guo-Ping Ai; Xiao-Hong Liu; Feng-Chao Wang; Tian-Min Cheng
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

4.  Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.

Authors:  Wen-He Zhao; Shi-Fu Wang; Wei Ding; Jian-Ming Sheng; Zhi-Min Ma; Li-Song Teng; Min Wang; Fu-Sheng Wu; Bing Luo
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

Review 5.  Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review.

Authors:  M W Saif; Shahrukh Hashmi; Daniel Zelterman; Khaldoun Almhanna; Richard Kim
Journal:  Int J Colorectal Dis       Date:  2007-10-02       Impact factor: 2.571

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.